Previous 10 | Next 10 |
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2021, on Thursday, March 10, 2022, after the market close. The Company will also post its fo...
The U.S. Food and Drug Administration (FDA) accepted Harrow Health's (NASDAQ:HROW) application seeking approval of AMP-100, an ocular surface anesthesia and intraoperative pain management during eye surgery. The FDA is expected to make a decision on the new drug application by Oct. ...
Receives PDUFA Date of October 16, 2022 Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) filing for AMP-100, the Company’s ...
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will present a company overview at the Aegis Capital Corp. Virtual Conference to be held on February 23-25,...
SRK Capital, LLC provides investment management services to an investment partnership, SRK Fund I, LP. Our portfolio is in no way comparable to an index and will not follow any in harmony. We were/are in the process of turning over a considerable portion of the portfolio into new ...
Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that its inaugural 2022 Corporate Transparency Report is now available under the Investors section of the Company’s website, harrowinc.com . The report focuses on Harrow Healt...
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the H.C. Wainwright BioConnect Conference to be held virtually on January 10-13, 2022. ...
Company Actively Dosing Patients for Phase 2 Pivotal Efficacy Study for MELT-300; Full Enrollment Followed by Readout on Topline Data Expected by End of Second Quarter of 2022 Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first‑in ...
Expands and Strengthens Portfolio of Product Offerings for U.S. Ophthalmic Surgical and Acute Care Markets Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced its acquisition of the exclusive U.S. commercialization rights of f...
Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021. The Nasdaq Biotechnology Index (NBI) is designed to meas...
News, Short Squeeze, Breakout and More Instantly...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...